Malignant tumours may be treated radically, with the intention of cure, or palliatively, the object being the relief or prevention of complications and the gain of as many months as possible of worth-while, satisfying life. The intelligent use of any effective method in the treatment of a patient with cancer involves taking calculated risks. If the chance of cure is good, reasonable risks and unpleasant side-effects are acceptable, although obviously not desirable. If the best that can be offered is a temporary improvement, serious side-effects and complications are no longer reasonable, as the quality of the patient's life is not improved and careful assessment is essential before such a method of treatment is used.
Assessment ofResults
The results of treatment can be assessed relatively easily vwhen attempting the cure of cancer. Results which are recorded as fiveor ten-year survival rates are meaningful, provided that all tumours are histologically proven, and that patients with cancer at similar stages are compared.
But the medical treatment of cancer is almost always palliative, and the assessment of results is infinitely more difficult. In published reports, 'remissions' produced by cytotoxic agents are often described without indicating the proportion of patients with symptomatic as opposed to objective improvement, making the report valueless. Frequently no hint is given of the natural history of the cancer under treatment. Many patients with incurable cancer live normal lives for years without treatment; spontaneous variation in apparently progressing cancer is quite frequent, particularly in the lymphomas, and there is well-documented evidence of spontaneous remissions of various types of malignant tumour (Everson & Cole 1959 , Smithers 1962 .
Subjective remission: Symptomatic improvement without simultaneous objective improvement is valueless as an indication of real tumour regression, unless every condition related to the patient is carefully documented. The most extraordinary symptomatic improvement can follow a more enthusiastic and optimistic therapeutic approach: new surroundings, including bed rest, careful nursing, and a change of treatment; the use of different analgesics, sedatives and tranquillizers and, in particular, the administration of amphetamine derivatives and steroids.
It is not surprising when a patient, in pain and misery at home, improves in the encouraging atmosphere of a hospital, especially when given a new drug, and it is sad to see how often this improvement is attributed solely to the new agent, and not at least partially credited to all the other factors. In 1948, Skinner, Carr & Denman reported good results with nitrogen mustard in the treatment of 25 patients with bronchial carcinoma. With remarkable insight, the authors stated: 'One indirect benefit from the drug is that these patients are observed more closely and symptoms can be treated as they arise. This, in itself, helps, raising the morale of these patients who were formerly told to go home and that nothing else could be done for them'.
Objective remission: In addition to spontaneous variations in the growth of a cancer, tumours may appear to regress when secondary infections are controlled and cytotoxic agents can affect the growth of bacteria, as well as cancer cells. A very effective use for 5-fluorouracil is in the treatment of moniliasis of the mouth, which usually responds rapidly to local applications of the drug. Steroids 66 may also reduce cedema in neighbouring tissues with some apparent reduction in the size of the tumour. Slight temporary variation in tumour size may therefore be misleading.
Lastly, tumours may appear to improve because of observer error. The doctor naturally hopes his patient will improve, but the measurement of palpable masses must not be prejudiced. The size of a few marker masses can be measured and recorded at each visit, without looking at the patient's previous notes. Information recorded in this way is factual and is uninfluenced by the observer's emotions.
Generally Available Cytotoxic Agents
Amongst the thousands of agents which have been investigated since the introduction of nitrogen mustard twenty years ago, there are a few well tried and generally acceptable cytotoxic agents, some of which are listed in Table 1 . They should not be referred to as chemotherapeutic agents, as this equates them with the relatively harmless group of drugs that are used for the treatment of bacterial infections. They are all cytotoxic agents, or cell poisons. For example, methotrexate is one of the most effective poisons ever invented. The cell enzyme which is irreversibly damaged by this drug has an affinity 100,000 times greater for methotrexate than for folic acid (Werkheiser 1961) . And yet, when carefully used, methotrexate is an extremely effective therapeutic weapon. All cytotoxic agents can inflict obvious, serious damage on normal tissues unless used carefully, but there are also more subtle dangers, particularly when they are used 'prophylactically' after the radical treatment of a primary tumour (Table  2) . It is highly probable that cancer cells circulate The effects of all agents in common use are nonspecific, damaging mainly any cell which is rapidly dividing in the blood stream in many patients without doing the patient any harm. The exact defence mechanism of the patient is not understood, but it probably operates through the reticuloendothelial and immunological systems, which are in themselves easily damaged by cytotoxic agents.
The haphazard administration of these agents to occasional patients may do harm rather than good, but used in this way neither the harm nor the good will be detectable. Prophylactic treatment can only be evaluated if it is used in a prospective strictly controlled trial and its occasional use must be strongly condemned.
If the patient is young, 'prophylactic' cytotoxic agents can produce genetic changes as effectively as ionizing irradiations.
Hodgkin's Disease Hodgkin's disease is often extremely sensitive, not only to ionizing irradiation but also to cytotoxic agents of all types. Published reports of malignant tumours treated with cytotoxic agents usually feature a high remission rate in Hodgkin's disease as opposed to other nonlymphomatous tumours. The selection of suitable agents has been made difficult by the variety which are now available. For routine use, the best agents are those which produce benefits with few serious side-effects; but even if the more toxic are excluded, there is still a profusion of agents which are strongly supported by authoritative medical opinion, and irrefutable enthusiasm.
The confusion is increased by the natural behaviour of the disease. The description, so common in standard textbooks, of a rubbery enlargement of the lymph nodes, steadily increasing in size and inevitably progressing to fatal termination, is usually incorrect. In early Hodgkin's disease, lymph node masses may disappear spontaneously for long periods; in the later stages palpable masses and constitutional manifestations may come and go every two or three months and only finally persist. As the disease progresses and increases in tempo, retreatment by any drug becomes less effective.
The natural fluctuations of Hodgkin's disease obviously mean that objective regression of a gland Section ofMedicine Duration ofregressions ranged from two to seventeen months *Adequate treatment: 5-10 mg daily for four weeks or longer * Regression: Measurable improvement in affected masses for two months or longer Duration of regressions ranged from two months to three years or more *Adequate treatment: 5-10 mg every 5-7 days (or more) for four weeks or longer * Regression: Measurable improvement in affected masses, for two months or longer mass cannot be attributed to a drug unless it has continued for at least four weeks, or preferably for at least two months. If any comparison between different series is to be possible, subjective improvement alone cannot be accepted as evidence of a remission. There are a few cytotoxic agents which are particularly useful in Hodgkin's disease. When a rapid improvement is required, intravenous nitrogen mustard is more efficient than most other agents and side-effects such as vomiting can be minimized by using individual doses of about 5 mg. Unfortunately, remissions are usually short lived.
The real problem arises when deciding which drug to use for long-term treatment. Of the alkylating agents, many are safe and effective, and in this country the most commonly used are chlorambucil (Galton et al. 1955 ) and cyclophosphamide. Chlorambucil has the advantages of not producing alopecia or htemorrhagic cystitis. Table 3 shows results obtained with the drug used intermittently, stopping 6-8 weeks after the maximum regression had occurred. More recently the drug has been used continuously for long periods, in average daily doses of 2-5 mg, without serious complications.
Vinblastine sulphate is another extremely effective and relatively nontoxic substance (Warwick et al. 1960) . The most important sideeffect limiting treatment is not depression of the bone marrow but the production of rapidly reversible neurotoxic effects . Cramps and parasthesia the day following each injection can be very severe, but the complication is dose dependent, with considerable variation from patient to patient. Early on in the trial of this drug we found that a tumour which recurred after treatment was stopped often failed to respond if the drug was started again. The drug is now continued indefinitely and some patients have had it for three years, with no cumulative toxic effects (Table 4) .
A recent addition to our armamentarium against Hodgkin's disease is the methylhydrazine derivative ibenzmethyzin (Natulan) . At a recently reported meeting (Jelliffe & Marks 1965 ) the results of treating 180 patients were reported by various authors. Remissions occurred in 122 patients (68%); unfortunately the same criteria for remissions were not observed by all the authors. A personal series is shown in Table 5 ). Depression of the bone marrow can certainly be produced but the most tiresome side-effect is nausea and vomiting which may sometimes completely prevent the use of the drug.
The similar duration of the remissions produced by this drug and nitrogen mustard, cyclophosphamide and vinblastine, is indicated clearly in Table 6 by Todd (1965) , who found the duration of remissions to vary from 3-8 to 3-4 months with all these agents. (A) . After eighteen months the pityriasis had slowly progressed (B), and after two years, patient developed a painless fluctuant swelling over the front of the tibia (c). X-ray examination showed an area of bone destruction (D) exploration of which revealed thick purulent fluid. Culture of this produced a heavy growth ofnocardia There are, therefore, now three types of drug which are chemically quite different, which do not produce cross-resistance, which are reasonably safe and which are apparently equally effective in the treatment of Hodgkin's disease.
Steroids: In addition to the nonspecific cytotoxic agents, prednisone and other cortisone derivatives are often used in the treatment of patients with Hodgkin's disease. Steroids are especially indicated by the presence of a hemolytic anmmia, bone marrow depression or very advanced disease which is not responding to other methods, but they must never be used without considerable care. Although they do not commonly produce objective improvement in Hodgkin's disease as opposed to lymphatic lymphomas, the symptomatic improvement may be very marked, and it is impossible to evaluate a cytotoxic agent if a steroid is used simultaneously. Many patients with Hodgkin's disease live for many years and the complication of long-term steroid therapy may shorten the patient's life. In a previously reported series of 165 patients (Jelliffe & Nabarro 1961) , 79 patients received 30 mg of prednisone, or more, daily for three months or longer and 37 developed side-effects which included diabetes, peptic ulceration, and serious infection. The infections were unusual and often fungal. More recently one of my patients with marrow depression responded well to prednisone but later developed spreading pityriasis versicolor (Fig IA,   B ) and, after two years, nocardial osteomyelitis (Fig 1c, D) , finally dying from nocardial septicemia.
It is reasonable to give cortisone derivatives to patients when there is a real indication for their use: the risks of long-term therapy are fully justified. But it is quite wrong to prescribe steroids for a patient whose disease could be controlled better by cytotoxicagents, or by radiotherapy.
Radiotherapy: Hodgkin's disease often responds very well to cytotoxic agents, but when it is reasonably localized it responds even better to radiotherapy. In many patients, the disease is apparently limited to one or several adjacent groups of lymph nodes and there are no constitutional symptoms; adequate radiotherapy may produce complete regression, and survival without evidence of disease may continue indefinitely (Fig 2) (Peters 1950 , Easson & Russell 1963 , Jelliffe 1965 There is often a long delay before the patient is referred for radiotherapy, usually because it is not realized that complete regression of the disease is Oiddekeos Oisea-se Micddlesex Hosplt&L 193oigsi It is not surprising that it is often accepted that nothing radical is possible, and patients are treated with cytotoxic agents when the disease is still localized, without seeking the advice of a surgeon or radiotherapist. Although the overall results of surgery are bad, and the survival rate after radiotherapy is appalling, these methods of treatment offer the only hope of cure. In addition, radiotherapy often offers the most rapid method of palliation.
It is right and proper that cytotoxic agents should be used to try to help those whose disease is beyond hope of cure, but there is no evidence Thomson (1955) . Just less than 40 % ofpatients with relatively limited disease, and no constitutional symptoms, survive for ten years or longer. (Reproduced from Jelliffe, 1965, by kind permission) possible and sometimes because a pathological report of 'benign Hodgkin's disease' induces in the doctor a false sense of security. With the passage of time, the disease spreads and radiotherapy must be more extensive and more likely to upset the patient. It is distressing to see how often patients with limited disease of this type are treated in a half-hearted way with cytotoxic agents and steroids, and only referred for radiotherapy long after the optimum time for this treatment has passed by.
Bronchial Carcinoma This form of cancer, which killed over 17,000 patients in 1964, is an example of a tumour which is exceptionally malignant and for which often little active treatment can be given.
If alI patients at all stages of the disease are considered, it is probable that not more than about 2 in 100 survive five years, aTter surgery.
Radiotherapy will cure occasional patients (Fig 3A, B) but, quite correctly, early cases are treated by surgery and most patients who come to a radiotherapy department have very advanced disease, often with widespread metastases, or else they are respiratory cripples who are unfit for surgery. Shaw et al. (1959) refer to a series of 1,180 patients of whom 50% were unsuitable for surgery, 15% underwent thoracotomy only and 35% (420) underwent resection; 38 of the series survived five years, 35 after resection and 3 after thoracotomy and radiotherapy. which shows convincingly that any cytotoxic agent prolongs life. It is disturbing to see published reports of trials of various cytotoxic agents carried out on 'all patients referred to the clinic,' because this suggests that a small number of potentially curable patients are being inadequately treated, because of the excessively pessimistic outlook of the doctor in charge. Palliation can often be achieved more rapidly with radiotherapy than chemotherapy, when the disease is localized: when the life expectancy is short it is quite wrong to keep a patient in hospital for weeks. The following is a personal example of patient mismanagement with chemotherapy.
Case 1 Woman, aged 62 Found to have large, poorly differentiated, bronchial carcinoma ( Fig 4A) which was treated with a cytotoxic agent because it was felt that the patient's medical knowledge would ensure that she would be greatly distressed by the implications of radiotherapy. Four weeks later there was no change in her symptoms or on chest X-ray ( Fig 4B) . Radiotherapy was started, with a marked response and loss of symptoms in ten days (Fig 4c) . Four months later, the chest X-ray showed a continued improvement (Fig 4D) , and the patient had no symptoms, but she died six months after the first treatment, with widespread metastases, having wasted one-sixth of her remaining life because of the trial of a cytotoxic agent.
Of all the cytotoxic agents so far used, none has produced any better rapid effects on bronchial carcinoma than nitrogen mustard. Cyclophosphamide is widely used and is equally effective (Grenville-Mathers & Trenchard 1964), but alopecia can be very distressing to a woman and a remission of two or three months is unsatisfactory if the patient spends all her time at home waiting for her hair to grow again.
There is no evidence at present that maintenance doses of any cytotoxic agent control the disease for long: trials will be necessary to show that one agent is better than another. Steroids may be valuable in the late stages of the disease, improving the appetite and general condition of the patient but, of course, these drugs can be just as dangerous as they can be with Hodgkin's disease if used too early in the course of the illness.
Breast Cancer This is an example of a cancer with extreme variation in its behaviour, which can be influenced by many factors. Many cytotoxic agents can reduce the size of masses and relieve symptoms, but the dose required to benefit the patient is often one which produces severe side-effects.
Personal experience has shown that thiotepa, chlorambucil, cyclophosphamide, methotrexate and vinblastine are all useful occasionally. But unpleasant toxic effects do occur and cytotoxic agents should not be used early in the course of the disease. When the disease is localized, surgery can cure many patients and when a tumour is inoperable radiotherapy is locally curative in about half the patients in which it is used, while it often affords excellent, rapid palliation of metastases. When the disease is generalized the best chance of success lies in hormone manipulation, and not with cytotoxic agents. The following case is exceptional, but illustrates what can be achieved with hormone therapy, without serious side-effects.
Case 2 Woman, aged 46 Admitted with large pleural effusion ( Fig 5A) five years after right radical mastectomy for carcinoma of the breast. Aspiration of the effusion and replacement with air showed nodular areas on the parietal pleura ( Fig 5B) . Thoracoscopy confirmed that nodules were present and biopsy showed tumour deposits identical in appearance with the original breast carcinoma. The patient was discharged from hospital with a gloomy letter to her general practitioner, and a six-week supply of intramuscular testosterone propionate, 100 mg daily. At the end of the six-week period, the testosterone injections were discontinued. Since then she has remained completely fit, and a recent chest X-ray, fourteen years later, shows no recurrence of the pleural effusion and only a little pleural thickening (Fig 5c) .
When the disease no longer responds to these methods, then cytotoxic agents may be tried, but not before. It may seem unreasonable to use these agents only at this stage, but their possible benefits are associated with more serious sideeffects than the other methods of treatment referred to. It is possible that they may be more useful in combination with hormone therapy or prophylactically after surgery, but the assessment of such methods requires carefully controlled groups, and they should never be 'tried out' on occasional patients unless the more orthodox methods have proved useless.
Conclusions
This paper is intended to convey two ideas: first, that cytotoxic drugs and other agents can be of very great benefit to patients with malignant disease but, secondly, that they can be dangerous if used incorrectly. They may produce serious side-effects, they may prevent adequate treatment by other methods, and when ambiguous results are published they encourage others to adopt the same viewpoint. Of course, there is nothing to stop any registered medical practitioner from using these potentially dangerous agents, without any specialized knowledge of cancer or any previous training in their use. When cytotoxic drugs are misused, it is probably because of the following chain of events: (1) The doctor, perhaps not fully aware of the natural history of the disease in his patient, feels excessively pessimistic about the chance of cure or palliation by conventional methods.
(2) The doctor is human and wishes to help the patient. (3) Chemotherapy is a harmless word; obviously, if a doctor is qualified to use penicillin, he is qualified to use a cancer chemotherapy agent. (4) The patient is human and if he knows the nature of his illness or has symptoms, he naturally wants something done. (5) Relatives are also human and want actionpreferably with the newest agent. And so, another course of a cytotoxic agent is given. Under these circumstances, it is difficult to judge who receives the greatest palliationthe patient, his relatives, or the doctor. Chemotherapy in malignant disease is still a developing subject. The agents now available are not very effective. Each agent must be uscd in a different way for the treatment of different conditions, and it is probable that we are not using the drugs we already have in the best possible way. It is possible also that for each particular condition there may be more than one effective way of using a drug, but there are so many variables to consider that it is very difficult to work out the best method except by trial and error. In a broad way we can consider the use and abuse of chemotherapy only in those conditions in which there is general agreement that chemotherapy is effective.
Before discussing particular situations in the treatment of leukemia and lymphoma I should like to make a general point. Once one accepts a patient suffering from malignant disease for chemotherapy one accepts that patient for the rest of his life and must be responsible for the management of his disease, from that time until he dies. It is very unfortunate that even now patients are sometimes treated by chemotherapy and are considerably improved, but are then sent away with no proper arrangements for follow up or adequate maintenance therapy. If they do not die at home they usually return to hospital in an advanced stage of relapse, and it may then be very difficult to treat them effectively again. I shall consider some critical aspects of the management of two acute and two chronic malignant conditions. In acute leukaemia in childhood, and in lymphoblastic lymphosarcoma presenting with massive mediastinal involvement, it is essential to induce remission rapidly; in the
